For patients with non-small cell lung cancer (NSCLC) ineligible for platinum-based chemotherapy, first-line atezolizumab monotherapy is associated with improved overall survival compared to single-agent chemotherapy, according ...
Aug 15, 2023
0
4
An innovative cancer drug discovered by scientists at The Institute of Cancer Research, London, is set to enter a new clinical trial.
May 5, 2023
0
3
Homologous Recombination Deficiency (HRD) is a biomarker that predicts ovarian cancer treatment with PARP inhibitors or breast cancer treatment with first-line platinum-based chemotherapy. However, limited research is documented ...
Apr 25, 2023
0
5
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone ...
Apr 16, 2023
0
4
The U.S. Food and Drug Administration approved the combination of tremelimumab (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer with no sensitizing ...
Nov 16, 2022
0
47
Early trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain type of non-small cell lung cancer (NSCLC).
Oct 28, 2022
0
11
The U.S. Food and Drug Administration has approved Roche's Tecentriq as adjuvant treatment following surgery and platinum-based chemotherapy, for adults with Stage II-IIIA non-small cell lung cancer, as determined by an FDA-approved ...
Oct 18, 2021
0
3
Epithelial ovarian cancer (EOC) is the most common lethal gynecological cancer. Ovarian cancer is usually treated with platinum-based chemotherapy; however, a significant number of patients are resistant to such treatments ...
May 27, 2021
0
1
Adding sintilimab to a regimen of gemcitabine and platinum demonstrates clinical benefit over gemcitabine and platinum alone as first-line therapy in patients with locally advanced or metastatic squamous cell non-small cell ...
May 25, 2021
0
1
Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) was well tolerated and provided clinical responses among patients with advanced BRCA- or PALB2-mutated pancreatic cancer sensitive to platinum-based chemotherapy, ...
Apr 2, 2019
0
1
